KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Prepaid Assets (2016 - 2025)

CRISPR Therapeutics AG's Prepaid Assets history spans 11 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 18.5% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 18.5%, while the annual FY2025 figure was $9.8 million, 18.5% up from the prior year.
  • Prepaid Assets for Q4 2025 was $9.8 million at CRISPR Therapeutics AG, down from $13.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $41.7 million in Q2 2022 and bottomed at $8.2 million in Q3 2024.
  • The 5-year median for Prepaid Assets is $21.1 million (2023), against an average of $22.9 million.
  • The largest annual shift saw Prepaid Assets skyrocketed 79.93% in 2021 before it plummeted 61.85% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $38.1 million in 2021, then fell by 0.97% to $37.7 million in 2022, then tumbled by 61.85% to $14.4 million in 2023, then plummeted by 42.26% to $8.3 million in 2024, then rose by 18.5% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Prepaid Assets are $9.8 million (Q4 2025), $13.4 million (Q3 2025), and $12.4 million (Q2 2025).